Natera, Inc. (NASDAQ:NTRA) is among the Best Healthcare Stocks.
On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests.
Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test. It offered no explanation for the decision.
The report noted that US District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that Natera, Inc. (NASDAQ:NTRA)'s statements actually misled customers. It still confirmed the jury's finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling.
Pixabay / Public Domian
On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests.
Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test. It offered no explanation for the decision.
The report noted that US District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that Natera, Inc. (NASDAQ:NTRA)'s statements actually misled customers. It still confirmed the jury's finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling.
Pixabay / Public Domian
4 months ago
